# COMPASS Pathways plc (CMPS)

> Source: Nexqual · https://nexqual.com/CMPS · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, COMPASS Pathways plc (CMPS), nexqual.com/CMPS" · informational, not investment advice.

**Price:** USD 11.18 (-3.87% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 11.63 · day 11.03–11.52 · 52w 4.88–15.87 · market cap $1.55B · NMS

## Key facts
- Analysts: Buy (mean 1.88 on a 1–5 scale) (16 analysts), mean target USD 23.75 (range 13–65).
- Total return with dividends: 1Y +78.0% vs S&P 500 +13.4%; 5Y -73.5% vs S&P 500 +76.9%.
- Next earnings: 2026-11-03, EPS estimate USD -0.33, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$83.2M | -$110M | -$137M | -$178M | -$179M | -$182M |
| Net income | -$71.7M | -$91.5M | -$118M | -$155M | -$288M | -$394M |
| EPS (diluted) | -$1.79 | -$2.16 | -$2.32 | -$2.30 | -$3.08 | — |
| Free cash flow | -$68.1M | -$106M | -$97.4M | -$119M | — | — |
| Cash + short-term investments | $273M | $143M | $220M | $165M | $150M | — |
| Total debt | — | $0K | $28.8M | $30.2M | $31.6M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 18.3x · Earnings yield -25.46% · Net cash $383M · EV $1.17B

## Analysts
Consensus Buy (mean 1.88 on a 1–5 scale), 16 analysts; mean target USD 23.75 (low 13, high 65).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | HC Wainwright & Co. | Target lowered | Buy | $70 → $65 |
| 2026-08-06 | Morgan Stanley | Target raised | Overweight | $17 → $18 |
| 2026-08-06 | RBC Capital | Target lowered | Outperform | $22 → $21 |
| 2026-08-06 | B. Riley Securities | Target raised | Buy | $17 → $22 |
| 2026-07-27 | Wells Fargo | Initiated | Equal-Weight | $13 |
| 2026-07-08 | HC Wainwright & Co. | Reiterated | Buy | $70 |
| 2026-07-08 | Evercore ISI Group | Upgrade | In-Line → Outperform | $8 → $21 |
| 2026-07-08 | Stifel | Target raised | Buy | $14 → $21 |
| 2026-07-07 | Morgan Stanley | Reiterated | Overweight | $17 |
| 2026-07-07 | Oppenheimer | Reiterated | Outperform | $20 |
| 2026-07-07 | BTIG | Target raised | Buy | $14 → $25 |
| 2026-06-26 | Canaccord Genuity | Target raised | Buy | $18 → $20 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +78.0% | -73.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +78.4% | -23.4% |
| Volatility (annualized) | 85.4% | 77.6% |
| Max drawdown | -38.2% (Feb 2026→Mar 2026) | -94.5% (Nov 2021→Mar 2025) |

## Peers (Medical Care Facilities)
AGL (agilon health, inc.) USD 89.71 -0.64% · PNTG (The Pennant Group, Inc.) USD 41.88 -0.83% · SNDA (Sonida Senior Living, Inc.) USD 33.82 -0.15% · NUTX (Nutex Health Inc.) USD 209.59 +1.70% · HCSG (Healthcare Services Group, Inc.) USD 25.3 +2.06% · ARDT (Ardent Health, Inc.) USD 12.27 -0.73%

## More
Full page: https://nexqual.com/CMPS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in CMPS's own 10-K filed 2026-03-24 (https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Hercules Capital, Inc. (HTGC) | "Our Loan Agreement with Hercules includes, and any future debt financing, if available, may involve agreements that include affirmative and negative restrictive covenants, such as limitations on our ability to incur addi…" |
| Partner | Delix Therapeutics | "We have a strategic investment in Delix Therapeutics, Inc., a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders." |
| Partner | Neuronetics, Inc. (STIM) | "In order to ensure we understand implementation challenges, we have entered into a number of collaboration agreements with numerous different types of health care delivery systems in the U.S. We have entered into collabo…" |

## Company outlook (8-K filed 2026-08-05)

- "The current cash position is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.33 | $-0.34 | -4.3% | $0 | 4 |
| Next quarter (ends 2026-12-31) | $-0.39 | $-0.41 | -5.5% | $0 | 4 |
| Current fiscal year (ends 2026-12-31) | $-1.50 | $-0.99 | +51.3% | $0 | 4 |
| Next fiscal year (ends 2027-12-31) | $-1.43 | $-1.06 | +35.6% | $39.7M | 3 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-03): ±17.1%; last 8 reports averaged ±10.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 83.1% | ±17.1% |
| 2026-12-18 | 56 | 79.0% | ±24.5% |
| 2027-01-15 | 84 | 84.8% | ±32.1% |
| 2027-02-19 | 119 | 78.1% | ±35.2% |
| 2027-05-21 | 210 | 92.6% | ±54.5% |